Menopause is associated with decreased estrogen production which leads to vasomotor symptoms and vulvovaginal atrophy. The woman may experience hot flushes, night sweats, dyspareunia or vaginal dryness. Spontaneous or natural menopause occurs when the final menstrual period is confirmed after 12 consecutive months of amenorrhea with no pathological cause. Induced menopause is the permanent cessation of menstruation after bilateral oophorectomy (ie surgical menopause) or iatrogenic ablation of ovarian function (eg pelvic radiation therapy, chemotherapy).
The neurokinin-3 receptor antagonist fezolinetant reduced the frequency and severity of menopause-associated vasomotor symptoms (VMS), according to results of the extension arm of the phase III Skylight 2 trial presented at ENDO 2022.
Individuals who experience menopause before age 50 years may be at an elevated risk of developing dementia, according to results of a UK study presented at the EPI Lifestyle Scientific Sessions 2022.
Women with laparoscopically confirmed endometriosis appear to have an elevated risk of early natural menopause (ENM), a recent prospective study has shown.
Dropping aspirin after 3 months of dual therapy with ticagrelor reduced bleeding in patients with diabetes who have undergone PCI* vs taking both agents for 1 year, the TWILIGHT-DM** study has shown, consistent with benefits seen in TWILIGHT for other high-risk patients.
In this final issue of our series, join us as we
look into the upcoming results of the pivotal EMPEROR trials, which will
investigate the use of empagliflozin in patients with either preserved or
reduced ejection fraction heart failure, with or without type 2 diabetes.
Understand why heart failure has such a high clinical burden, and the great
unmet need in providing solutions for it.